Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series
Clinical Colorectal Cancer · 2024
DOI: 10.1016/j.clcc.2024.01.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Tao Pan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Cancer Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Aff…. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms, Brain Neoplasms, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Sichuan Province Health Commission.
Abstract (Originalsprache)
BACKGROUND: Although ipilimumab plus nivolumab have significantly improved the survival of metastatic colorectal cancer (CRC) with mismatch repair deficient (dMMR) /microsatellite instability-high (MSI-H), the data on neoadjuvant setting is limited. PATIENTS AND METHODS: We enrolled 11 patients with advanced dMMR/MSI-H CRC. 10 patients were locally advanced and 1 was metastatic. Ten patients were treated with 1 dose of ipilimumab (1 mg/kg) and 2 doses of nivolumab (3 mg/kg), and 1 patient was treated with 1 dose of ipilimumab (1 mg/kg) and 2 doses of nivolumab (3 mg/kg) with 2 cycles. All the patients underwent surgery after immunotherapy. The aim of the study was to evaluate the safety and short-term efficacy of this strategy. RESULTS: Pathologic responses were observed in 11/11 (100%) dMMR/MSI-H tumors, with 9/11 (81.8%) achieving complete responses. Among these 9 cases with complete responses, 1 achieved a radiological noncomplete response after treatment with 1 dose of ipilimumab (1 mg/kg) and 2 doses of nivolumab (3 mg/kg), so another cycle of treatment with 1 dose of ipilimumab (1 mg/kg) and 2 doses of nivolumab (3 mg/kg) was administered, followed by surgery. The postoperative pathological evaluation was a complete response. Seven patients (63.6%) developed grade I/II adverse events. No patients developed grade III/IV adverse events or postoperative complications. CONCLUSION: Neoadjuvant immunotherapy with ipilimumab plus nivolumab induced tumor regression with a major clinical and pathological response in advanced dMMR/MSI-H CRC. Notably, patients do not achieve a complete response to neoadjuvant immunotherapy, additional neoadjuvant immunotherapy may offer benefits. Further research is needed to assess the long-term efficacy of this strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Cancer Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Techno…
- Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of C…
Förderung
- Sichuan Province Health Commission
Zitieren
APA
Pan, T., Yang, H., Wang, W. Y., Rui, Y. Y., Deng, Z. J., Chen, Y. C., Liu, C., & Hu, H. (2024). Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.01.002
Vancouver
Pan T, Yang H, Wang WY, Rui YY, Deng ZJ, Chen YC, et al. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.01.002
BibTeX
@article{Pan2024,
author = {Pan, Tao and Yang, Hui and Wang, Wu-Yi and Rui, Yuan-Yi and Deng, Zi-Jian and Chen, Yung-Chang and Liu, Chao and Hu, Hai},
title = {Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series},
journal = {Clinical Colorectal Cancer},
year = {2024},
doi = {10.1016/j.clcc.2024.01.002}
}
EUVIMED